MedTrace Logo

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-25

No results posted yet for this study

Summary

This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.

The names of the study drugs involved in this study are:

* Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax)
* Poly-ICLC (Hiltonol)
* CDX-301
* Nivolumab (Opdivo)
* Pembrolizumab (Keytruda)

Conditions

Interventions

DRUG

CDX-301

Administered as an injection given underneath the skin

BIOLOGICAL

NEOVAX

Personalized neoantigen vaccine administered as an injection given underneath the skin

DRUG

Nivolumab

Administered intravenously (IV)

DRUG

Pembrolizumab

Administered intravenously (IV)

Sponsors & Collaborators

Principal Investigators

  • Patrick A Ott, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-03
Primary Completion
2027-12-31
Completion
2030-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930783 on ClinicalTrials.gov